Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study - Quiz - MDSpire

Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study

  • By

  • Pan Ma

  • Yumeng Zhou

  • Xin Zhang

  • Quanfeng Zhao

  • Yu Peng

  • Hailong Jiang

  • Linli Xie

  • Yan Liao

  • June 24, 2026

  • 0 min

Share

Original Source(s)

Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study

  • by Pan Ma, Yumeng Zhou, Xin Zhang, Quanfeng Zhao, Yu Peng, Hailong Jiang, Linli Xie, Yan Liao

  • June 24, 2026

Related Content

The mechanism of action, clinical significance, and research progress of tumor antigen-specific T cells in the treatment of HCC

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients

Reporting of Rurality, Deprivation, and Socioeconomic Characteristics in Cancer Clinical Trials: A Systematic